Skip to content

Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome

Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02459808
Enrollment
0
Registered
2015-06-02
Start date
2015-05-31
Completion date
Unknown
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Guillain-Barre Syndrome

Brief summary

Constipation is a common condition among patients with Guillain-Barré Syndrome. It is believed, that the constipation is caused by autonomic neuropathy. However, the severity of the constipation, and its relation to autonomic function have not previously been studied.

Interventions

None listed

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Guillain-Barré Syndrome * Ability to swallow the capsules used to assess GITT * Ability to give meaningful informed consent to participate in the study

Exclusion criteria

* Major abdominal disorders * Severe acute comorbidity * Known cancer * Pregnancy * Other known neurological disorder * Use of laxatives one week before inclusion. (Patients will be excluded if medication with laxatives is started during the one week GITT measurement)

Design outcomes

Primary

MeasureTime frame
Gastrointestinal transit time (GITT) [in days]The measurement takes one week to perform. The investigators aim to start the measurement within one week after diagnosis.

Secondary

MeasureTime frameDescription
Association between heart rate variability (HRV) and GITTThe first HRV measurement is performed within one week after diagnosis. The second is performed 7 days after the first.Linear regression with GITT as dependent variable, and high frequency power spectral density analysis of the heart rate (HF) as the independent variable. The mean HF of the first and second HRV measurement is used for this regression.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026